Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-019150
Filing Date
2025-02-12
Accepted
2025-02-12 19:11:54
Documents
1
Period of Report
2025-02-12

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 6538
  Complete submission text file 0000950170-25-019150.txt   8239
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Issuer) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O VICKERS VANTAGE CORP. I 1 HARBOURFRONT AVENUE, #16-06 SINGAPORE U0 098632
Business Address C/O VICKERS VANTAGE CORP. I 1 HARBOURFRONT AVENUE, #16-06 SINGAPORE U0 098632 (646) 974-8391
Vickers Venture Fund VI Pte Ltd (Reporting) CIK: 0001839162 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-42513 | Film No.: 25616637